Illumina (ILMN) Financial Analysis & Valuation | Quarter Chart
Illumina (ILMN)
ILMNPrice: $135.78
Fair Value: 🔒
🔒score
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive he... more
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its p... more
Description
Shares
| Market Cap | $20.63B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Medical - Diagnostics & Research |
| Country | US | CEO | Jacob Thaysen |
| IPO Date | 2000-07-28 | CAGR | 0.42% |
| Employees | 8,970 | Website | www.illumina.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | 2.63% | Total Yield | 2.63% |
ILMN chart loading...
Fundamentals
Technicals
| Enterprise Value | $19.86B | P/E Ratio | 21.24 |
| Forward P/E | 23.07 | PEG Ratio | 4.05 |
| P/S Ratio | 4.7 | P/B Ratio | 6.86 |
| P/CF Ratio | 18.42 | P/FCF Ratio | 20.86 |
| EPS | $5.44 | EPS Growth 1Y | -190.33% |
| EPS Growth 3Y | -119.28% | EPS Growth 5Y | 28.79% |
| Revenue Growth 1Y | 1.25% | Gross Margin | 0.67% |
| Operating Margin | 0.21% | Profit Margin | 0.19% |
| ROE | 0.33% | ROA | 0.13% |
| ROCE | 0.18% | Current Ratio | 1.75 |
| Quick Ratio | 1.36 | Cash Ratio | 0.7 |
| Debt/Equity | 0.81 | Interest Coverage | 12.09 |
| Altman Z Score | 4.82 | Piotroski Score | 6 |